Viewing RCC with a DNA Methylation Lens ENHANCES Understanding of ICI Resistance

Clin Cancer Res. 2023 Apr 3;29(7):1170-1172. doi: 10.1158/1078-0432.CCR-22-3574.

Abstract

Clear-cell renal cell carcinoma tumors with an enhancer demethylator phenotype (TED) harbor a worse prognosis and derive less clinical benefit from immunotherapy. The TED phenotype may help predict immunotherapy resistance. See related article by Lu et al., p. 1279.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / genetics
  • Carcinoma, Renal Cell* / pathology
  • DNA Methylation
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / genetics
  • Kidney Neoplasms* / pathology
  • Phenotype
  • Prognosis

Substances

  • Immune Checkpoint Inhibitors